EMERGE is a global, randomized, multicenter, placebo-controlled Phase 3 trial that will evaluate claseprubart 300mg/2mL S.C. dosed Q2W and Q4W ...

In the first part of the CIDP study, 75% of the initial group of patients showed meaningful improvement after receiving claseprubart, Dianthus said.

Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today ...

Dianthus Therapeutics is positioned as a category-expanding biotech, leveraging convenience and safety to address autoimmune neuromuscular and rheumatology markets. DNTH boasts a robust balance sheet ...

Octagon Capital Advisors sold 470,000 shares of Dianthus Therapeutics in the first quarter; the estimated transaction value was $27.22 million (based on quarterly average prices). The quarter-end ...

Develops monoclonal antibody therapeutics, with its lead candidate, DNTH103, targeting severe autoimmune and inflammatory diseases and in phase 1 clinical trials. Operates a clinical-stage ...

Shares of Dianthus Therapeutics (DNTH) fell more than 20% in the premarket on Wednesday after efficacy concerns prompted Sanofi (SNY) to halt a late-stage trial of riliprubart, an experimental therapy ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...